Skip to main content
. 2016 Apr 22;7(21):31534–31549. doi: 10.18632/oncotarget.8925

Figure 7. Meso64-TR3's enhanced activity profile is dominated by its much enhanced binding affinity and rapid surface tethering to MUC16-positive cancer cells.

Figure 7

OVCAR3 cells were exposed for the indicated time points to TR3, Meso-TR3 and Meso64-TR3 (218 pM each). Then, the cells were washed three times with PBS in order to remove the unbound biologics, followed by treatment of all cells with a constant dose SW IV-134 for additional 24 hours (8 μM), after which cell viability was determined. Please note that in order to achieve close to complete target cell death, Meso64-TR3 required only a five minute binding interval, not matched by TR3 and not even Meso-TR3. P < 0.003.